Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New Data
Did you know that noncovalent BTK inhibitors are potentially the answer to the development of resistance to covalent BTK inhibitors?
Credit available for this activity expires: 4/5/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/971263?src=mkm_podcast_addon_971263
Create your
podcast in
minutes
It is Free